Conclusions
There was no difference in the magnitude of decrease of the AVNBCL and VABCL relative to the magnitude in decrease of the SCL at each incremental dose of dobutamine. However, the AVNBCL, the VABCL and the SCL decreased significantly from baseline with each incremental dose of dobutamine (except the 3% decrease in SCL from baseline to 5 mcg/kg/min dobutamine was not statistically significant). Dobutamine was also seen to enhance retrograde AV nodal conduction in two out of three patients who displayed no retrograde conduction at baseline. While hypotension and arrhythmia-inductions were noted, no significant hypertensive nor further adverse events were noted, which deems dobutamine a safe alternative to isoproterenol for EPS.
Other Members of the Dobutamine Study Group:
Aushim Kokroo, M.D.1, Parmanand Dasrat, M.D.1, Ali Seyar Rahyab1, M.D.1